1
|
Scott M, Clarke D, Lipsitz Y, Brandwein H, Allickson J, Alzebdeh D, Aleksic S, Kraft C, Lhu L, Cornetta K. Transitioning from development to commercial: risk-based guidance for critical materials management in cell therapies. Cytotherapy 2020; 22:669-676. [PMID: 32713719 DOI: 10.1016/j.jcyt.2020.06.011] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/06/2020] [Revised: 06/07/2020] [Accepted: 06/24/2020] [Indexed: 11/25/2022]
Abstract
A key hurdle to ensuring patient access to cell and gene therapies (CGTs) and continued growth of the industry is the management of raw materials. The combination of rapid growth, individual product and process complexity and limited industry-specific guidance or awareness presents non-obvious risk mitigation challenges for transitioning from development to clinical application. Understanding, assessing and mitigating the varied raw material risks for CGT products during product and clinical development are critical for ensuring smooth transitions into commercialization and for preventing interruption of product supply to patients. This article presents a risk-based approach driven by concerns for patient safety that can help focus and coordinate efforts to address the most critical risk factors. Highlighted are some of the highest risk materials common to the manufacture of many CGTs, including the primary starting material, culture media, reagents and single-use components. Using a hypothetical gene-edited cell therapy as an example, we describe the general manufacturing process and subsequently incorporate the described methodology to perform a sample risk assessment. The practical approach described herein is intended to assist CGT manufacturers and suppliers in actively assessing materials early in development to provide a basic starting point for mitigating risks experienced when translating CGT products for clinical and long-term commercial application.
Collapse
Affiliation(s)
- Michael Scott
- International Society for Cellular Therapy Process and Product Development Subcommittee, Vancouver, Canada; BlueRock Therapeutics, Toronto, Canada
| | - Dominic Clarke
- International Society for Cellular Therapy Process and Product Development Subcommittee, Vancouver, Canada; HemaCare Corporation, Northridge, California, USA
| | - Yonatan Lipsitz
- International Society for Cellular Therapy Process and Product Development Subcommittee, Vancouver, Canada; Sana Biotechnology, Cambridge, Massachusetts, USA
| | - Harvey Brandwein
- International Society for Cellular Therapy Process and Product Development Subcommittee, Vancouver, Canada; Cook Myosite, Indianapolis, Indiana, USA
| | - Julie Allickson
- International Society for Cellular Therapy Process and Product Development Subcommittee, Vancouver, Canada; Wake Forest Institute for Regenerative Medicine, Winston-Salem, North Carolina, USA
| | - Dalia Alzebdeh
- Wake Forest Institute for Regenerative Medicine, Winston-Salem, North Carolina, USA
| | - Sasha Aleksic
- International Society for Cellular Therapy Process and Product Development Subcommittee, Vancouver, Canada; Fujifilm Irvine Scientific, Irvine, California, USA
| | - Crystal Kraft
- International Society for Cellular Therapy Process and Product Development Subcommittee, Vancouver, Canada; West Pharmaceuticals, Exton, Pennsylvania, USA
| | - Lexan Lhu
- International Society for Cellular Therapy Process and Product Development Subcommittee, Vancouver, Canada; PBS Biotech, Camarillo, California, USA
| | - Kenneth Cornetta
- Indiana University School of Medicine, Indianapolis, Indiana, USA
| |
Collapse
|